Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Sezary Syndrome 2Melanoma 2Sarcoma, Ewing 1Sarcoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Hepatitis 1Hematologic Neoplasms 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Mycophenolic Acid 2vedolizumab 1Ursodeoxycholic Acid 1Steroids 1Sofosbuvir 1Ribavirin 1Prednisone 1Photopheresis 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Methoxsalen 1Infliximab 1Azathioprine 1Adrenal Cortex Hormones 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hepatitis × Methoxsalen × Clear all
NCT07619898 2026-06-02

PHOENIX-ECP

Therakos LLC

Phase 2 Not yet recruiting
112 enrolled
Dermatologic

Colitis, Hepatitis, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡